- Investing Ideas
- Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
Vitrolife
Market Cap: SEK 12.1b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 89.55
7D
-1.6%
1Y
-35.4%
BioGaia
Market Cap: SEK 12.1b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 119.70
7D
1.3%
1Y
21.0%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.36
7D
5.7%
1Y
-26.9%